<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125901">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696474</url>
  </required_header>
  <id_info>
    <org_study_id>CAD0111</org_study_id>
    <secondary_id>EudraCT number 2011-006329-42</secondary_id>
    <nct_id>NCT01696474</nct_id>
  </id_info>
  <brief_title>Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease</brief_title>
  <acronym>CAD0111</acronym>
  <official_title>Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, phase II, open label study will enroll patients with chronic cold
      agglutinin disorder. A single course of Bortezomib will be given at the dose of 1,3 mg/sqm
      iv on days 1, 4, 8, 11.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on its activity in MM, single agent Bortezomib was tested in phase II trials in
      lymphoplasmacytic lymphoma, the disorder most frequently associated with CAD, and achieved
      40-80% responses. These striking clinical responses indicate that proteasome activity is
      critical for the survival of immunoglobulin-secreting cells. The resolution of transfusion
      requirement in two patients with refractory CAD associated with IgMk monoclonal gammopathy
      has been reported after treatment with a short course of Bortezomib. It may be interesting
      to test the efficacy of Bortezomib in a larger series of patients with refractory CAD,
      idiopathic or associated with an otherwise asymptomatic B cell clonal disorder, and to
      evaluate the duration of clinical benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients who become transfusion-free after Bortezomib therapy.</measure>
    <time_frame>After 3 months from study entry.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative proportion of patients transfusion-free at three months after Bortezomib therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who have never been transfused with a &gt;2g hemoglobin rise compared to baseline.</measure>
    <time_frame>After 3 months from study entry.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of CTC grade 3 and 4 adverse events.</measure>
    <time_frame>After 12 months from study entry.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of the incidence of CTC grade 3 and 4 adverse events during and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration in months of transfusion independence.</measure>
    <time_frame>At 12 months from study entry.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on the underlying clonal B cell disorder.</measure>
    <time_frame>At 3 months from study entry.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Refractory Cold Agglutinin Disease</condition>
  <arm_group>
    <arm_group_label>Bortezomib therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single course of Bortezomib will be given at the dose of 1,3 mg/sqm  iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>Bortezomib therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic cold agglutinin disorder requiring or with a hemoglobin
             concentration below 10g/L determined at least monthly during the two months before
             entering the trial;

          -  Failure of at least one previous treatment attempt;

          -  Hemoglobin level assessment;

          -  Cold agglutinin (CA) titer at 4°C of 64 or higher;

          -  Written informed consent.

        Exclusion Criteria:

          -  Presence of a concomitant lymphoproliferative disorder requiring specific treatment
             for reasons other than cold agglutinin related hemolytic anemia;

          -  Preexisting peripheral neuropathy;

          -  Known hypersensitivity to Bortezomib;

          -  Non-cooperative behaviour or non-compliance;

          -  Psychiatric diseases or conditions that might impair the ability to give informed
             consent;

          -  Patients who are pregnant (women of childbearing potential must have a negative serum
             pregnancy test). Post-menopausal women must be amenorrhoic for at least 24 months to
             be considered of non-childbearing potential. Male and female patients must agree to
             employ an effective barrier method of birth control throughout the study and for up
             to 3 months following discontinuation of study drug.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Rossi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.C. Ematologia e Dipartimento di Oncologia Medica Spedali Civili - Brescia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi, Dr.</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Flavia Salvi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Baraldi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia e Trapianti Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>21125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika BORLENGHI, Dr.</last_name>
      <email>erika.ok@libero.it</email>
    </contact>
    <investigator>
      <last_name>Erika BORLENGHI, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale Centro per le Malattie del Sangue</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ercole DE BIASI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto BOSI, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Alberto BOSI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvana Franca Capalbo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Silvana Franca Capalbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppina Spinosa, Pr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale &quot;Santa Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo De Blasio, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Angelo De Blasio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia Bernuzzi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo - Unità di Ematologia e Trombosi</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Cattaneo, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Marco Cattaneo, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agostino CORTELEZZI, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Agostino CORTELEZZI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe GRITTI, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera S. Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Maria POGLIANI, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Enrico Maria POGLIANI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca GAIDANO, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Monia LUNGHI, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gianluca GAIDANO, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monia LUNGHI, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia con trapianto di midollo - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerlando Quintini, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Gerlando Quintini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cinzia Maugeri, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecilia Caramatti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Cecilia Caramatti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Rossetti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo CASTAGNOLA, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Patrizia ZAPPASODI, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Carlo CASTAGNOLA, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia ZAPPASODI, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Fioritoni, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Fioritoni, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Sau, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Luigi Cavanna, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maura Brugiatelli, MD</last_name>
      <phone>39-965-397-111</phone>
      <email>mbrugiat@tiscalinet.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Merli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Merli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annalisa Imovili, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO di Ematologia Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pellegrino Musto, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Pellegrino Musto, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Pietrantuono, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Leone, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe LEONI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca LAURENTI, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavila, Pr.</last_name>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorella Melillo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDO Ematologia 2 AOU S.Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo MARMONT, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Filippo MARMONT, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernesta AUDISIO, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda U.L.S.S.9 - U.O. di Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Gherlinzoni, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Filippo Gherlinzoni, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Gottardi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Candoni, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Zaja, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona Puglisi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico G. B. Rossi - Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Pizzolo, MD</last_name>
      <email>giovanni.pizzolo@univr.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni PIZZOLO, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dino DE VENERI, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eros DI BONA, Pr.</last_name>
      <email>dibona@hemato.ven.it</email>
    </contact>
    <investigator>
      <last_name>Eros DI BONA, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory cold agglutinin disease</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>blood-transfusion</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Agglutinins</mesh_term>
    <mesh_term>Cold agglutinins</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
